Claims for Patent: 4,704,273

Summary for Patent: 4,704,273

Title:	Methods and materials for treatment of rheumatoid arthritis
Abstract:	Disclosed are methods and compositions useful for alleviating the symptoms of rheumatoid arthritis. In preferred embodiments, the compositions are administered in essentially minute \"neutralizing\" doses. The compositions comprise mixtures of histamine, immunoglobulin G provocative of RF formation or an immunologically active fraction thereof, collagen and either attenuated measles virus or immunologically active fraction thereof. Illustratively significant relief of symptoms of arthritis disease symptoms is achieved through parenteral (e.g., subcutaneous or sublingual) administration of such compositions.
Inventor(s):	McMichael; John (Cambridge Springs, PA)
Assignee:
Application Number:	06/833,998
Patent Claims:	1. A method for alleviating the symptoms of rheumatoid arthritis comprising administering to the disease victim an effective amount of a composition comprising a mixture of histamine, immunoglobulin G provocative of rheumatoid factor formation or an immunologically active fraction thereof, collagen and attenuated measles virus or an immunologically active fraction thereof. 2. The method of claim 1 wherein histamine is administered in the form of a water soluble histamine salt. 3. The method of claim 1 wherein said composition comprises, in unit dosage form, from about 8.8.times.10.sup.-6 to about 5.5.times.10.sup.-3 mg of histamine phosphate. 4. The method of claim 1 wherein said composition comprises, in unit dosage form, from about 0.1 to about 0.005 mg of chromatographically pure immunoglobulin G. 5. The method of claim 4 wherein the immunoglobulin G is human immunoglobulin G. 6. The method of claim 1 wherein said composition comprises, in unit dosage form, from about 0.4 to about 10 TCID.sub.50 of attenuated measles virus. 7. The method of claim 1 wherein said composition comprises, in unit dosage form, from about 4.times.10.sup.-3 to about 1.times.10.sup.-1 mg of collagen. 8. The method of claim 1 wherein said composition is administered parenterally. 9. The method of claim 8 wherein said composition is administered subcutaneously or sublingually. 10. A composition of matter comprising a mixture of histamine, immunoglobulin G provocative of RF formation, collagen and attenuated measles virus. 11. A composition according to claim 10 wherein histamine is in the form of a water soluble histamine salt. 12. A composition according to claim 10 comprising, in unit dosage form, from about 8.8.times.10.sup.-6 to about 5.5.times.10.sup.-3 mg of histamine phosphate. 13. A composition according to claim 10 comprising, in unit dosage form, from about 0.1 to about 0.005 mg of chromatographically pure immunoglobulin G. 14. A composition according to claim 13 wherein the immunoglobulin is human immunoglobulin G. 15. A composition according to claim 10 comprising, in unit dosage form, from about 0.4 to about 10 TCID.sub.50 of attenuated measles virus. 16. A composition according to claim 10 comprising, in unit dosage form, from about 4.times.10.sup.-3 to about 1.times.10.sup.-1 mg of collagen.

Details for Patent 4,704,273

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2040-01-28
Alk-abello, Inc.	HISTATROL	positive skin test control-histamine	Injection	103754	09/29/1950		2040-01-28
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2040-01-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2040-01-28
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2040-01-28